CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus
Jae Hyun Bae, Hyung Jin Choi, Kang Ik Kevin Cho, Lee Kyung Kim, Jun Soo Kwon, Young Min Cho
Diabetes Metab J. 2020;44(2):248-259.   Published online November 4, 2019
DOI: https://doi.org/10.4093/dmj.2019.0018

Excel Download

Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus
Diabetes & Metabolism Journal. 2020;44(2):248   Crossref logo
Link1 Link2 Link3

Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
Diabetes. 2018;67(Supplement_1):   Crossref logo
Link1 Link2

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
Diabetes Therapy. 2020;11(9):1965-1982   Crossref logo
Link1 Link2 Link3

Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
The Journal of Korean Diabetes. 2019;20(3):149   Crossref logo
Link1 Link2 Link3

Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus
Clinical Therapeutics. 2016;38(10):e1   Crossref logo
Link1 Link2

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus—A Systematic Review and Meta-analysis
Diabetes. 2018;67(Supplement_1):   Crossref logo
Link1 Link2

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
Diabetes mellitus. 2017;20(3):220-230   Crossref logo
Link1 Link2 Link3

Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ ‐64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose‐ranging study
Clinical Obesity. 2021;11(2):   Crossref logo
Link1 Link2 Link3

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
Diabetes mellitus. 2017;20(4):286-298   Crossref logo
Link1 Link2

SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus
Journal of the Endocrine Society. 2019;3(Supplement_1):   Crossref logo
Link1